Arrowhead Pharmaceuticals, Inc.
82.63USD
-2.4800 (-2.91%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 243.2M | 240.7M | 3.6M | 829.4M | 461.2M | 339.9M |
| Q1 | 27.4M | 62.5M | 3.6M | 2.5M | 264.0M | 42.9M |
| Q2 | 151.8M | 146.3M | 0.0 | 542.7M | 73.7M | — |
| Q3 | 32.4M | 15.8M | 0.0 | 27.8M | 75.3M | — |
| Q4 | 31.6M* | 16.1M* | 0.0* | 256.5M* | 58.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.67 | -1.92 | -5.00 | -.010 | -3.54 | -4.80 |
| Q1 | -.600 | -.390 | -1.24 | -1.39 | .220 | -1.34 |
| Q2 | .410 | .450 | -1.02 | 2.75 | -.930 | — |
| Q3 | -.680 | -.960 | -1.38 | -1.26 | -1.36 | — |
| Q4 | -.811* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -1.03* |
| -1.42* |
| -.178* |
| -1.54 |
| — |